Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284).
暂无分享,去创建一个
P. Wipf | J. Lazo | M. Egorin | J. Eiseman | E. Joseph | S. Pan | B. Joo | R. Parise | J. Lan | Jianxia Guo | Beomjun Joo
[1] B. Day,et al. Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells. , 2006, Chemical research in toxicology.
[2] Chuan-ming Xie,et al. Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. , 2006, Bioorganic & medicinal chemistry letters.
[3] P. Hatcher,et al. Mechanism of arylating quinone toxicity involving Michael adduct formation and induction of endoplasmic reticulum stress. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[4] B. Ganem,et al. Selective inhibition of MCF-7(piGST) breast tumors using glutathione transferase-derived 2-methylene-cycloalkenones. , 2005, Journal of medicinal chemistry.
[5] Y. Sugimoto,et al. A novel cinnamic acid derivative that inhibits Cdc25 dual‐specificity phosphatase activity , 2005, Cancer science.
[6] Bernard Ducommun,et al. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases , 2005, Molecular Cancer Therapeutics.
[7] P. Wipf,et al. Redox regulation of Cdc25B by novel cell active quinolinediones , 2005 .
[8] P. Wipf,et al. Synthesis and Biological Evaluation of Caulibugulones A—E. , 2004 .
[9] Ivet Bahar,et al. Discovery and Characterization of Novel Small Molecule Inhibitors of Human Cdc25B Dual Specificity Phosphatase , 2004, Molecular Pharmacology.
[10] V. Baldin,et al. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. , 2004, Cancer research.
[11] G. Guella,et al. Kinetic studies of glutathione S-transferase-catalysed processes through on-line liquid chromatography–electrospray mass spectrometry , 2004 .
[12] P. Wipf,et al. NAD(P)H:Quinone Oxidoreductase-1-Dependent and -Independent Cytotoxicity of Potent Quinone Cdc25 Phosphatase Inhibitors , 2004, Journal of Pharmacology and Experimental Therapeutics.
[13] J. Lazo,et al. Dual G1 and G2 Phase Inhibition by a Novel, Selective Cdc25 Inhibitor 7-Chloro-6-(2-morpholin-4-ylethylamino)- quinoline-5,8-dione* , 2002, The Journal of Biological Chemistry.
[14] P. Wipf,et al. Dual-specificity phosphatases as targets for antineoplastic agents , 2002, Nature Reviews Drug Discovery.
[15] A. Miyauchi,et al. Expression of cdc25A and cdc25B proteins in thyroid neoplasms , 2002, British Journal of Cancer.
[16] Peter Wipf,et al. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. , 2002, Molecular pharmacology.
[17] P. Wipf,et al. Synthesis and biological evaluation of structurally highly modified analogues of the antimitotic natural product curacin A. , 2002, Journal of medicinal chemistry.
[18] S. Kitamura,et al. Reductive metabolism of p,p'-DDT and o,p'-DDT by rat liver cytochrome P450. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[19] P. Wipf,et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. , 2001, Journal of medicinal chemistry.
[20] M Monden,et al. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. , 2000, Cancer research.
[21] J. Bolton,et al. Role of quinones in toxicology. , 2000, Chemical research in toxicology.
[22] L. Mao,et al. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. , 1998, Cancer research.
[23] V. Jevtovic-Todorovic,et al. Direct measurement of melphalan conjugation with glutathione: studies with human melanoma cells and mammalian liver. , 1992, The Journal of pharmacology and experimental therapeutics.
[24] P. Wipf,et al. NAD ( P ) H : Quinone Oxidoreductase-1-Dependent and-Independent Cytotoxicity of Potent Quinone Cdc 25 Phosphatase Inhibitors , 2004 .
[25] Robin Johnson,et al. The role of NAD(P)H: quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells , 2004, Cancer Chemotherapy and Pharmacology.
[26] Bernard Ducommun,et al. Inhibitors of the CDC25 phosphatases. , 2003, Progress in cell cycle research.
[27] M. Monden,et al. Overexpression of CDC 25 B Phosphatase as a Novel Marker of Poor Prognosis of Human Colorectal Carcinoma 1 , 2000 .
[28] G. Powis,et al. Metabolism and reactions of quinoid anticancer agents. , 1987, Pharmacology & therapeutics.